RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
205 hedge funds and large institutions have $2.58B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2023 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 47 increasing their positions, 65 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
205
Holders Change
+37
Holders Change %
+22.02%
% of All Funds
3.28%
Holding in Top 10
9
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+200%
% of All Funds
0.14%
New
63
Increased
47
Reduced
65
Closed
26
Calls
$222M
Puts
$110M
Net Calls
+$111M
Net Calls Change
+$121M
Top Buyers
| 1 |
PA
Perceptive Advisors
New York
|
+$197M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$66.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$33.1M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$31.6M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$28.5M |
Top Sellers
| 1 |
FAM
Fred Alger Management
New York
|
-$121M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$76M |
| 3 |
Millennium Management
New York
|
-$49.9M |
| 4 |
Morgan Stanley
New York
|
-$44.6M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$43.2M |
